Vericel Corporation Культура компании

Mr. Daniel R. Orlando, also known as Dan, has been the Chief Operating Officer of Vericel Corporation since August 2013. Mr. Orlando served as Chief Business Officer of Aastrom Biosciences, Inc. since May 2013 to August 2013 and served as its Chief Commercial Officer since September 5, 2012. Mr. Orlando served as the Chief Executive Officer and Interim President of Aastrom Biosciences, Inc. from December 14, 2012 to March 01, 2013. Mr. Orlando served as Vice President of Sales at Takeda Pharmaceuticals North America, Inc. Mr. Orlando was responsible for managing all sales functions including Sales Operations, Sales Training & Development and a Diabetes and Cardiovascular Care, Neurosciences and Medical Center sales force of more than 2,000 individuals. He was with Takeda Pharmaceuticals for over 13 years in executive leadership positions in marketing, sales and business development, served as Vice President of Business Development for North and South America. Previously, he was with Abbott Laboratories for more than 11 years in progressive sales and marketing roles. During his career, he has helped to establish dozens of pharmaceutical brands including, most significantly, Actos(R). Under Dan's leadership, Actos(R) became the top brand in diabetes. Mr. Orlando joined Takeda in 1999 as the Director of Marketing for Actos??? (pioglitazone HCl) - Takeda's drug for type 2 diabetes. From 2003 to 2005 he managed both the West and East Diabetes and Cardiovascular Care sales forces as a Zone director, leading about 400 to 700 sales representatives. Prior to joining Takeda, he worked at Abbott Laboratories for more than 11 years, holding a variety of roles that combined sales with marketing from overseeing product launches to managing and training sales teams to, where he began his career, holding a variety of field sales positions in South Florida. He holds an M.B.A. in management from Florida Atlantic University and a Bachelor of Science degree from the University of Florida.

Ms. Jacquelyn Fahey Sandell, also known as Jacqui, has been Vice President and General Counsel of Vericel Corporation since April 19, 2016 and has been its Corporate Secretary since February 2, 2016. Ms. Sandell served as Vice President of Legal Affairs at Vericel Corporation since February 2, 2016 until April 19, 2016. Ms. Sandell joined Vericel in 2015 and has more than twenty years of experience both as in-house counsel in the biotechnology and pharmaceuticals industries and in private practice. She has considerable experience in healthcare and pharmaceutical law and regulation, business development, commercial business transactions, mergers and acquisitions, intellectual property licensing, securities law and compliance. She served as Associate General Counsel for Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co). She served as Senior Corporate Counsel for Genzyme Corporation, providing legal support to the Genzyme Genetics division and corporate development. Prior to joining Genzyme, she began her legal career at Shearman & Sterling in their New York, London and Paris offices before joining Allen & Overy in their Rome office, specializing in mergers and acquisitions and securities law. She holds a B.A. from Duke University and a J.D., magna cum laude, from Boston University School of Law.

Dr. David P. Recker, also known as Dave, M.D., FACR, FACP has been Chief Medical Officer at Neuralstem, Inc. since November 8, 2017. Dr. Recker is the founding manager of JJK Consulting. Dr. Recker has been the Chief Medical Officer of Vericel Corporation since April 1, 2014 and served as Acting Chief Medical Officer until April 1, 2014. He has been responsible for clinical development, regulatory affairs, medical and scientific affairs, pharmacovigilance, statistics and data management. Dr. Recker has more than 20 years of experience in drug development at Takeda Global Research and Development, where he served as Senior Vice President for Clinical Science. Dr. Recker served as Vice President of Clinical Science at Takeda Global Research & Development Center Inc. Dr. Recker's was responsible for overseeing and directing clinical research for a variety of pharmacologic agents, particularly in the area of endocrinology and metabolism. He joined the Takeda team in 2002. Dr. Recker had responsibility for multiple development programs in a variety of therapeutic areas. He is a Fellow of the American College of Physicians as well as a Fellow of the American College of Rheumatology. He did his fellowship in training at the National Institutes of Health. He holds an M.D. with Distinction from the University of Michigan where he did his internship and residency and was Chief Resident in Internal Medicine.

Mr. Gerard J. Michel, MS, MBA, has been Chief Financial Officer and Vice President of Corporate Development at Vericel Corporation (formerly, Aastrom Biosciences Inc) since June 2014 and served as its Corporate Secretary. Mr. Michel served as the Chief Financial Officer, Vice President of Corporate Development and Treasurer of Biodel Inc. from November 20, 2007 to May 30, 2014 and also served as its Chief Accounting Officer. He oversaw strategic development, fundraising and capital structure management, marketing efforts, investor relations and financial reporting and internal controls. Mr. Michel served as Principal Accounting Officer and Chief Financial Officer of NPS Pharmaceuticals, Inc. from October 2003 to November 2007 and Vice President of Corporate Strategy. He served as Vice President of Corporate Development of NPS Pharmaceutical from July 2002 to November 19, 2007. At NPS, he closed numerous financial and strategic transactions, managed financial reporting and served as a key liaison for investors and analysts. Prior to joining NPS in July 2002, Mr. Michel served as a Principal with the consulting firm of Booz-Allen & Hamilton from June 1995 to July 2002, where he worked with numerous pharmaceutical companies, biotech firms and healthcare service firms on both strategic and operational issues from 1995 to July 2002. From 1988 to 1995, he was with Lederle Labs, serving in Marketing, Sales and Corporate Development roles, both domestically and international. He served as a Director of EP Medsystems Inc. since January 11, 2007. Mr. Michel holds a B.S., M.S. in Microbiology and an M.B.A. from the University of Rochester.

Mr. Michael Halpin, also known as Mike, has been Senior Vice President of Quality & Regulatory Affairs at Vericel Corporation since April 10, 2017. Mr. Halpin formerly served as vice president, North American region regulatory head at Sanofi Genzyme, with responsibility for Sanofi Genzyme's rare disease, immuno-inflammatory, multiple sclerosis and other business unit products. Previously, Mr. Halpin served as vice president, regulatory affairs for Genzyme's biosurgery division, with regulatory oversight of all biosurgery and cell and gene therapy products, including Carticel??, Epicel??, and MACI??. Prior to Genzyme, he held a number of regulatory, quality and clinical affairs positions at several medical device companies, including Abbott/MediSense, C.R. Bard and Abiomed. Mr. Halpin received his master's degree in biomedical engineering and bachelor's degree in biochemistry from the University of Virginia.

Gerard Michel serves as the CFO and Vice President of Corporate Development of Vericel Corporation. Gerard started at Vericel Corporation in June of 2014. Gerard currently resides in Greater New York City Area.

Roland DeAngelis serves as the Vice President, Commercial Operations - Cell Therapies of Vericel Corporation. Roland started at Vericel Corporation in March of 2017. Roland currently resides in Greater Boston Area.